Impact of risk of generalizability biases in adult obesity interventions: A meta‐epidemiological review and meta‐analysis
Authors
Beets, Michael W.
Burkart, Sarah
Jones, Alexis
Ioannidis, John P. A.
Weaver, R. Glenn
Okely, Anthony D.
van Sluijs, Esther
Jago, Russell
Turner‐McGrievy, Gabrielle
Thrasher, James
Li, Xiaoming
Publication Date
2021-11-14Journal Title
Obesity Reviews
ISSN
1467-7881
1467-789X
Language
en
Type
Article
This Version
AO
VoR
Metadata
Show full item recordCitation
Beets, M. W., von Klinggraeff, L., Burkart, S., Jones, A., Ioannidis, J. P. A., Weaver, R. G., Okely, A. D., et al. (2021). Impact of risk of generalizability biases in adult obesity interventions: A meta‐epidemiological review and meta‐analysis. Obesity Reviews https://doi.org/10.1111/obr.13369
Description
Funder: Sue and Bob O'Donnell
Abstract
Summary: Biases introduced in early‐stage studies can lead to inflated early discoveries. The risk of generalizability biases (RGBs) identifies key features of feasibility studies that, when present, lead to reduced impact in a larger trial. This meta‐study examined the influence of RGBs in adult obesity interventions. Behavioral interventions with a published feasibility study and a larger scale trial of the same intervention (e.g., pairs) were identified. Each pair was coded for the presence of RGBs. Quantitative outcomes were extracted. Multilevel meta‐regression models were used to examine the impact of RGBs on the difference in the effect size (ES, standardized mean difference) from pilot to larger scale trial. A total of 114 pairs, representing 230 studies, were identified. Overall, 75% of the pairs had at least one RGB present. The four most prevalent RGBs were duration (33%), delivery agent (30%), implementation support (23%), and target audience (22%) bias. The largest reductions in the ES were observed in pairs where an RGB was present in the pilot and removed in the larger scale trial (average reduction ES −0.41, range −1.06 to 0.01), compared with pairs without an RGB (average reduction ES −0.15, range −0.18 to −0.14). Eliminating RGBs during early‐stage testing may result in improved evidence.
Keywords
REVIEW, REVIEWS, intervention, pilot, scaling, translation
Sponsorship
National Health and Medical Research Council (APP1154507, APP1176858)
National Heart, Lung, and Blood Institute (F31HL158016, F32HL154530, R01HL149141)
National Institute of General Medical Sciences (P20GM130420)
Identifiers
obr13369
External DOI: https://doi.org/10.1111/obr.13369
This record's URL: https://www.repository.cam.ac.uk/handle/1810/330818
Rights
Licence:
http://creativecommons.org/licenses/by-nc-nd/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk